Objective: Lactoferrin is a pleiotropic glycoprotein of the innate immune system with known effects on immunomodulation and cell differentiation. To gain an insight into the interaction among obesity, inflammation and insulin action, we aimed to examine the effects of lactoferrin on adipogenesis and the response to insulin in human hepatocarcinoma (HepG2) and 3T3-L1 cell lines. Design: The cells were cultured with increasing lactoferrin concentration under non-inflammatory, inflammatory and standard conditions. The response to insulin was evaluated through 473Ser AKT phosphorylation. The effects of lactoferrin on adipogenesis were studied through the expression of different lipogenic markers, AMP-activated protein kinase (AMPK) activation, retinoblastoma (Rb) activity and Oil Red O staining in 3T3-L1 cells. Results: Lactoferrin increased dose-dependent insulin-induced 473Ser AKT phosphorylation in both cell lines. Inflammationinduced decreased 473Ser AKT phosphorylation was also rescued by lactoferrin. In addition, lactoferrin led to increased p172Thr AMPK during 3T3-L1 differentiation and to decreased adipogenesis (as shown by decreased expression of fatty acid synthase, acetyl-coenzyme A carboxylase-a and peroxisome proliferator-activated receptor-g in parallel with decreased formation of lipid droplets). Lactoferrin also increased dose-dependent Rb activity (expression and hypophosphorylation) during 3T3-L1 differentiation. Conclusion: Lactoferrin administration increased insulin-induced 473Ser AKT phosphorylation, even in those conditions wherein the response to insulin was downregulated, and led to blunted adipogenesis in the context of increased p172Thr AMPK and Rb activity.
Introduction
Obesity-associated metabolic dysregulation is increasingly envisioned as a chronic inflammatory disease. Macrophage infiltration into the adipose tissue may have a role in insulin resistance-associated inflammatory activity. Macrophagesecreted factors are known to block adipogenesis and insulin action in adipocytes and hepatocytes by the downregulation of insulin receptor sustrate-1 (IRS-1), leading to decreased AKT phosphorylation. [1] [2] [3] [4] The mechanisms through which pro-inflammatory cytokines, like tumor necrosis factor-a, interleukin-6 (IL-6) and IL-1b interact with cellular insulin signal transduction cascades have been described in the last years. [5] [6] [7] [8] [9] Lactoferrin is a pleiotropic glycoprotein (80 kDa) and a prominent component of the first line of mammalian host defense, acting on specific lactoferrin receptors that exist in a variety of cells, like monocytes, lymphocytes, adipocytes, hepatocytes and endothelial cells. 10 Lactoferrin expression is upregulated in response to inflammatory stimuli. 10 Lactoferrin is able to bind and buffer several pathogen associated molecular patterns, such as lipopolysaccharide (LPS), viral components and soluble components of the extracellular matrix. 11 This ability is associated with the putative lactoferrin anti-inflammatory activity, as shown in several studies. 12 Lactoferrin administration led to decreased release of tumor necrosis factor-a and IL-6 in mice, [13] [14] [15] to downregulated pro-inflammatory cytokine production in different cell lines acting via nuclear factor-kB, 16 and to decreased LPSinduced binding of nuclear factor-kB to the tumor necrosis factor-a promoter. 16 Lactoferrin also participates in the regulation of cellular growth and differentiation. 17, 18 In primary osteoblasts, lactoferrin stimulated proliferation and differentiation and even acted as a survival factor, thereby, inhibiting apoptosis induced by serum withdrawal and also inhibiting osteoclastogenesis in a murine bone marrow culture. 19 To the best of our knowledge, effects of lactoferrin on the response to insulin (through p473Ser AKT) have never been explored. We aimed to investigate the effects of different lactoferrin concentrations on insulin-induced 473Ser AKT phosphorylation in human hepatocarcinoma (HepG2) and 3T3-L1 fibroblast mouse cell lines. We also evaluated whether lactoferrin rescues the decreased 473Ser AKT phosphorylation induced by dexamethasone and macrophage conditioned media in the 3T3-L1 cell line. Finally, we studied the effects of lactoferrin on 3T3-L1 adipocyte differentiation. Lactoferrin effects on insulin-induced p473Ser AKT phosphorylation in HepG2 and 3T3-L1 cell lines HepG2 cells, undifferentiated 3T3-L1 and pre-differentiated 3T3-L1 cells were incubated in serum-free DMEM containing 25% non-stimulated THP-1 conditioned media (MCM) or 25% LPS-stimulated THP-1 conditioned media (LPS-MCM). Co-treatment with different lactoferrin (Sigma-Aldrich, Madrid, Spain) concentrations (0.01, 0.1, 1 and 10 mM) for 24 h was used to assay the effects on: (1) insulin-induced 473Ser AKT phosphorylation; (2) insulin-induced 473Ser AKT phosphorylation after MCM and LPS-MCM stimulus; and (3) insulin-induced 473Ser AKT phosphorylation after dexamethasone treatment. In this latter experiment, undifferentiated 3T3-L1 cells were incubated in media containing 20 mM glucose, 10 % fetal bovine serum, 100 U ml À1 penicillin and 100 ìg ml À1 streptomycin, and insulin, dexamethasone and isobutylmethylxanthine (INS-DEX-IBMX) mixture, containing 10 mg ml À1 bovine insulin (SigmaAldrich), 0.5 mM dexamethasone (Sigma-Aldrich) and 0.5 mM isobutylmethylxanthine (Sigma-Aldrich) for 2 days. After 24 h, all samples were stimulated with insulin (100 nM for 10 min) and the experiments were carried out in triplicate. The relative quantity of p473Ser AKT, AKT and insulin receptor was measured by western blot.
Materials and methods

Lactoferrin effects on 3T3-L1 differentiation
The embryonic fibroblast mouse cell line 3T3-L1 (American Type Culture Collection) was maintained in DMEM containing 20 mM glucose, 10 % fetal bovine serum, 100 U ml
À1
penicillin and 100 mg ml À1 streptomycin. Two days after confluence, INS-DEX-IBMX mixture was added for 2 days, followed by 5 days with insulin alone. Lactoferrin (0.1, 1 and 10 mM) was added in two steps of the differentiation process, and the experiment was carried out in triplicate. AKT/ AKT phosphorylation during the differentiation process (day 0, 1, 2, 4 and 7) under lactoferrin (1 mM) administration vs vehicle.
Western blot analysis
Cell lysates were washed in ice-cold PBS followed by homogenization assay using radio immunoprecipitation assay (RIPA) lysis buffer (10X: 0.5 M Tris-HCl, pH 7.4, 1. 5M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10mM EDTA; Upstate, AMPK, AMPK, FASN, PPAR-g, Rb and anti-b-actin antibodies (Santa Cruz Biotechnology, Quimigen S.L., Madrid, Spain), insulin receptor (UpstateMillipore, Billerica, MA, USA) and GLUT-4 (Chemicon International, Billerica, MA, USA). Anti-rabbit immunoglobulin G and anti-mouse immunoglobulin G coupled to horseradish peroxidase was used as secondary antibody. Horseradish peroxidase activity was detected by chemiluminescence and quantification of protein expression was carried out using Scion image software (Scion Corp., Frederick, MD, USA).
Cytokine antibody array
A commercially available Custom Human Cytokines Antibody Array for Bionova (Ray Biotech, Norcross, GA, USA) was used to determine the level of the 20 cytokines cited in Figure 1 . The assay was carried out according to the manufacturer's instructions. In brief, membranes were blocked with a blocking buffer, and then incubated overnight with 1 ml of the culture supernatants at 4 1C. The membranes were washed and incubated with 1 ml of primary biotin-conjugated antibody at room temperature for 2 h. After washing, 2 ml of horseradish peroxidase-conjugated streptavidin was added and incubated for 30 min at room temperature. The membranes were developed by using detection buffer, exposed to X-ray film and processed by autoradiography. Detectable spots were scanned and analyzed for densitometry with Scion Image software.
MTT-based cell viability assays and cell counting
The ability of lactoferrin to affect 3T3-L1 and HepG2 cell viability was determined using a standard colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) reduction assay. Cells in exponential growth were harvested by trypsinization and seeded at a concentration of approximately 2.5 Â 10 3 cells per 200 ml per well into 96-well plates, and left during an overnight period for attachment. The medium was then removed and fresh medium with various concentrations of human lactoferrin (hLf) (1, 10, 20 mM) were added to the cultures in parallel. Control cells without agents were cultured using the same conditions with comparable media changes. Compounds were not renewed during the entire period of cell exposure. After treatment (5 days), the medium was removed and replaced by fresh drug-free medium (100 ml per well), and MTT (5 mg ml À1 in PBS) was added to each well at a volume of 1/10. After incubation for 2-3 h at 37 1C, the supernatants were carefully aspirated, 100 ml of dimethyl sulfoxide were added to each well, and the plates agitated to dissolve the crystal product. Absorbances were measured at 570 nm. The cell viability effects from exposure of cells to each compound were analyzed as percentages of the control cell absorbances, which were obtained from control wells treated with appropriate Lactoferrin and insulin response JM Moreno-Navarrete et al concentrations of the compounds vehicles that were processed simultaneously. For each treatment, cell viability was evaluated as a percentage using the following equation: (A 570 of treated sample/A 570 of untreated sample) Â 100. Cell counting was assessed by trypan blue dye exclusion using a Neubauer hemocytometer, after 7 days differentiation of 3T3-L1 cells, in triplicate.
MCM LPS-MCM
Sensitivity to hLf was then expressed as the percentage of cell viability for each concentration of the drug. Percent cell viability for 1, 10 and 20 mM of hLf was 97.9, 86.3 and 87.4, respectively, in 3T3-L1 cells; and 94.9, 85.4 and 80.9, respectively, in HepG2 cells.
Statistical analysis
Data are expressed as the mean ± s.e.m. The experiments were carried out in triplicate. The effects of lactoferrin treatment were evaluated using unpaired t-test and Wilcoxon's test. Conditioned media from unstimulated THP-1 cells did not change 473Ser AKT phosphorylation significantly in these HepG2 cells. Again, lactoferrin increased the response to insulin dose dependently (Figure 2b ). In the absence of insulin, we did not observe any increase in p473Ser AKT after hLf administration. However, using 150 mg of total protein in the western blot (instead of 50 mg of total protein), we found a significant increase in p473Ser AKT with the two highest lactoferrin concentration (1 and 10 mM, respectively) ( Figure 3a ). Lactoferrin administration did not increase total AKT or insulin receptor protein levels (Figure 3b ). 
Results
LPS effects on THP-1 cells
Human lactoferrin effects on 3T3-L1 differentiation
The increase in lipid droplets, the synthesis of lipogenic proteins and AMPK activity ( p172Th rAMPK) were evaluated during 3T3-L1 differentiation. Administration of lactoferrin led to dose-dependent reduction in lipid droplets ( Figure 5 ). In fact, at the highest lactoferrin dose (10 mM), lipid accumulation was similar to that present in non-differentiated 3T3-L1 fibroblasts ( Figure 6 ).
In agreement with these observations, the lipogenic proteins, FASN, ACC and PPAR-g were downregulated after lactoferrin treatment (1 and 10 mM). FASN decreased by 44 and 66%, respectively (Po0.001 and o0.001), ACC by 22% and 96% (P ¼ 0.03 and Po0.001, respectively) and PPAR-g by 73% and 84% (Po0.001 and o0.001, respectively) compared with untreated, differentiated 3T3-L1 fibroblasts ( Figure 7) .
Furthermore, hLf led to 11.4 and 15.3-fold (P ¼ 0.03 and 0.009, after 1 and 10 mM, respectively) increased phospho- 
Human lactoferrin effects on Rb activity during 3T3-L1 differentiation
Retinoblastoma activity (as showed by increased Ser807/811 Rb phosphorylation and decreased total Rb levels) decreased Human lactoferrin effects on cell viability during 3T3-L1 differentiation When differentiating 3T3-L1 cells, the cell number was significantly increased when compared with non-differentiated Impaired insulin action in these cells was also rescued by increasing lactoferrin concentration. Under inflammatory conditions, lactoferrin dose dependently rescued the low response to insulin in both HepG2 and 3T3-L1 cells.
Lactoferrin could have an insulinotropic activity, increasing AKT phosphorylation on serine 473 in the absence of insulin. Different antioxidant and anti-inflammatory actions of lactoferrin could also be involved in the improvement of insulin action under inflammatory conditions. Recently, Yagi et al. 22, 23 reported that lactoferrin suppressed the adipogenic differentiation of MC3T3-G2/PA6 cells. Lactoferrin co-treatment decreased lipid droplets and the mRNA expression of several adipogenesis markers (CEBP-a, PPAR-g, aP2 and adiponectin) while inducing osteogenesis (increasing the expression of Runx2, osteocalcin and Sox9). These findings fit with existing hypotheses that a reciprocal or inverse relationship exists between adipogenesis and osteogenesis in the marrow microenvironment. 24, 25 However, these authors did not study the effects of insulin. According to our data, lactoferrin also downregulated 3T3-L1 differentiation, decreasing the formation of lipid droplets. Red oil density was negatively associated with lactoferrin concentrations. Lacto- Lactoferrin and insulin response JM Moreno-Navarrete et al ferrin also decreased dose dependently different lipogenic proteins (FASN, ACC and PPAR-g) in parallel with increased AMPK activation ( p172Thr AMPK) and GLUT-4 levels. This latter observation could be related with the lactoferrin interference on adipogenic differentiation. In fact, AMPK activation leads to increased fat oxidation by the upregulation of the transcription factor NRF-1, which stimulates mitochondrial biogenesis and inhibits both lipolysis and lipogenesis, affecting directly the enzymes engaged in lipid metabolism and downregulating PPAR-g expression. 26 Hyperphosphorylation of Rb (inhibition) is necessary to promote clonal expansion and adipocyte differentiation of 3T3-L1 cells. 27, 28 We found decreased Rb activity and protein levels during 3T3-L1 cells differentiation. Lactoferrin increased dose dependently Rb activity (hypophosphorylation and Rb expression) in parallel to its inhibitory effects on adipogenesis. Thus, lactoferrin could inhibit adipogenic differentiation through the increase of hypophosphorylated Rb (Rb activity) levels, inducing cell cycle arrest. 29 In MTTbased cell viability assays to evaluate lactoferrin cytotoxicity, we found that lactoferrin (10 mM) decreased cell viability of 3T3-L1 by only 15%. Cell counting corroborated the negative effects of lactoferrin on 3T3-L1 expansion during the differentiation process. We did not find changes in GLUT-4 expression between pre-adipocytes and adipocytes. We used dexamethasone as a component of the differentiation cocktail that could have influenced the results. In fact, dexamethasone did not change GLUT-4 expression levels while decreasing GLUT-4 translocation and glucose uptake in 3T3-L1 cells. 30 Dexamethasone also led to decreased GLUT-4 expression in adipocytes in one study, 31 
Study limitations
We studied the lactoferrin effects during a 24 h co-incubation. The observed effects suggest a mechanism whereby changes in gene/protein expression are required. Shorter exposure times need to be further evaluated to test if the same enhancement of insulin-stimulated AKT activation can be achieved. The 24 h conditioned media may still contain LPS, and some the actions of hLf may be explained (a least in part) by its ability bind to and buffer LPS. The effects of hLf on increased insulin sensitivity and GLUT-4 expression should be evaluated further in vivo.
To the best of our knowledge, this is the first study showing an insulin sensitizing effect of lactoferrin, even under conditions associated with insulin resistance (proinflammatory medium and dexamethasone administration). Further investigation is necessary to evaluate the possible benefits of this protein in metabolic disturbances associated with insulin resistance and obesity.
Conflict of interest
The authors declare no conflict of interest.
